entertainment -WSS

entertainment

author：leisure time 2025-08-21 08:27:10 - browse：9443

research funding, medical devices — APStock

WASHINGTON — A federal district judge on Monday granted the Biden administration’s request to dismiss a lawsuit challenging Medicare’s new drug price negotiation program from the drug industry lobbying organization PhRMA.

The move is an early but positive sign for the Biden administration in a legal fight that could stretch for years, as a host of major drugmakers, including Merck, Bristol Myers Squibb, and Johnson & Johnson, have also filed lawsuits over the constitutionality of Medicare’s new powers. The first round of drug negotiations is ongoing, and a judge heard oral arguments in a challenge brought by AstraZeneca just last month.

Newsletters

Sign up for D.C. Diagnosis

Washington never stops. Cut through the noise with our essential updates on health care politics and policy

Please enter a valid email address. Privacy Policy

The National Infusion Center Association and the Global Colon Cancer Association are also plaintiffs in PhRMA’s lawsuit. The judge dismissed the National Infusion Center Association from the case because it did not have subject matter jurisdiction to bring the lawsuit. And because NICA was the only party to the lawsuit that resides in Texas, the judge tossed out the case in its entirety.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： ASCO: Palliative care found as helpful given virtually as in person

knowledge

WSS

Ionis drug prevents swelling attacks due to hereditary angioedema

Pancreatic cancer early detection could be helped by AI

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Investment in vaccine development is lagging, report finds

Boston competes with Raleigh

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

explore

entertainment

Sign up for D.C. Diagnosis

focus

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Hepatitis C has a cure — but many Americans still lack access to it

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Hepatitis C has a cure — but many Americans still lack access to it

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

How to save PrEP access — and even expand it

Innovation in antibiotics is ailing. 'Brain drain' may kill it

State Dept. review finds Biden bears some blame for Afghanistan failures

Zyn nicotine pouches become unlikely player in latest culture war

entertainment

How to increase colonoscopy rates? Looks like an AI can help

BMI, flaws aside, is found to be useful estimate of body fat in youth

Philips to halt sales of sleep apnea machines in U.S.

FTC sues over Novant Health acquisition of two N.C. hospitals

Syphilis numbers in the United States reach record heights

Woman returns to dialysis after doctors remove transplanted pig kidney

Wikipedia

knowledge

hotspot

hotspot